Background: Current vitiligo therapies require many months of treatment and often result in disappointing outcomes. Treatment with a 308-nm excimer laser has shown promising results in patients with vitiligo.
Objective: This controlled prospective trial studied the effectiveness of the 308-nm excimer laser for treating vitiligo in Asians.
Methods: Thirty-four patients (14 males and 20 females) with localized vitiligo were enrolled in the study. Vitiligo patches were treated using a 308-nm excimer laser. Lesions were treated twice weekly for 13 weeks. The treatment was started with 50 to 100 mJ/cm2 (according to site) and increased by 50 mJ/cm2 in every session until erythema appeared. Patients were treated for 25 sessions, or until 100% repigmentation, whichever was achieved first. The overall response rate was assessed clinically and by comparison of photographs before and after treatment by two independent investigators.
Results: Twenty-nine patients (12 males and 17 females) completed the study. Lesions on the face responded better than elsewhere on the body. The least responsive areas were the hands and feet. The average number of treatment sessions prior to repigmentation was 11. Untreated control patches remained unchanged. In higher skin phototypes the response was more favorable. There was no significant correlation between the age of the patients and their response to treatment.
Conclusion: The use of the 308-nm excimer laser for the treatment of vitiligo is effective, relatively safe, and more convenient compared to other available modalities of treatment for stable vitiligo with small patches. However, similar to other modalities of treatment, the therapeutic effect is mainly dependent on the location of vitiligo lesions.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Excimer light versus topical methotrexate 1% hydrogel in treatment of scalp psoriasis: clinical and dermoscopic study.
Arch Dermatol Res
January 2025
Dermatology and Venereology Department, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.
One of the most frequently impacted locations by psoriasis is the scalp. It is seen in about 80% of psoriasis cases worldwide, and its treatment is challenging. To compare the efficacy and safety of excimer light versus topical methotrexate (MTX) 1% hydrogel in treatment of scalp psoriasis.
View Article and Find Full Text PDFShort-term efficacy and safety of upadacitinib combined with 308 excimer light versus upadacitinib alone and 308 excimer light alone in patients with progressing facial vitiligo.
Arch Dermatol Res
January 2025
Department of Dermatology, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Henan University People's Hospital, Zhengzhou, 450003, China.
Patients with progressing facial vitiligo who had been treated with upadacitinib, 308 nm excimer light and upadacitinib combined with 308 nm excimer light were selected for retrospective analysis and comparison of their efficacy and safety. Efficacy was evaluated using the Vitiligo Area Severity Index (VASI) and Dermatology Life Quality Index (DLQI) at baseline, after 8 weeks, and after 20 weeks. The progression of skin lesions was monitored through reflectance confocal microscopy (RCM), while adverse reactions were documented.
View Article and Find Full Text PDFA randomized prospective study to compare the efficacy of 308-nm light-emitting diode and 308-nm excimer lamp in the treatment of facial vitiligo.
Arch Dermatol Res
January 2025
Department of Physiotherapy, Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing, 210042, China.
Background: Previous studies have proven that 308-nm light-emitting diode(308-nm LED)and 308-nm excimer lamp(308-nm MEL) are effective in treating vitiligo, but there is a lack of comparison of their efficacy for facial lesions.
Objective: To evaluate and contrast the treatment success rates of 308-nm LED versus 308-nm excimer lamp in managing facial lesions among patients suffering from stable non-segmental vitiligo.
Methods: The enrolled 119 patients with 145 lesions were randomly assigned to receive 308-nm LED or 308-nm MEL for two months.
A pilot study of tofacitinib citrate with 308-nm excimer laser for the treatment of vitiligo.
Clin Exp Dermatol
December 2024
Department of Dermatology, People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, PR China.
Background: Vitiligo is a clinically prevalent acquired skin disorder characterized by depigmentation. Currently, the therapeutic options for vitiligo are restricted, and numerous issues exist, such as a prolonged treatment course, unsatisfactory therapeutic efficacy, adverse reactions, and a high propensity for recurrence after treatment cessation.
Aim: To assess the safety and efficacy of combined treatment involving oral tofacitinib citrate (TC) and a 308-nm excimer laser (EL), with the aim of discovering a rapid and effective treatment approach to minimize the side effects of various drugs.
Assessment of Efficacy on the Treatment of Localized Vitiligo With a Combination of 308 nm Excimer Light and 2940 Erbium Laser: A Retrospective Study.
J Cosmet Dermatol
December 2024
Department of Dermatology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Background: A 308 nm excimer light is an effective treatment for vitiligo, with fewer treatment times, rapid obvious effects, relatively complete pigment recovery, good patient compliance, and safe and effective treatment for children. The disadvantage of this treatment is that some patients have a plateau during which the skin lesion reduction rate slows down or stalls after multiple treatments.
Methods: Treatment data were collected from all vitiligo patients in the Dermatology Department, distinguishing between those who underwent 308 nm excimer light treatment alone and those who received a combination of 308 nm excimer light and 2940 erbium laser treatment.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!